eNeura, a Baltimore-based company that makes a device to treat migraines, closed a Series D investment round.
The round was led by Camden Partners Nexus, the Inner Harbor firm’s venture fund focusing on biomedical technology. Also participating were the Abell Foundation, entrepreneur David Oros, Marc Blum, and the Fischell family, who also founded the company. The amount of funding raised in the round was not disclosed.
University of Maryland BioPark–based eNeura makes a device called sTMS mini that sends a magnetic pulse into the brain to treat and prevent migraine headaches in a process known as neuromodulation. It’s seen as a replacement for drugs, according to CEO David Rosen. While the device must be prescribed, it is portable and could be used by patients outside a clinic.
“Neuromodulation is the next great advancement in migraine treatment and prevention and we are pleased to have the opportunity to support eNeura’s commercial efforts to expand sTMS access for patients,” Jacob Vogelstein, Managing Partner at Camden Partners Nexus, said in a statement.
The company reported receiving FDA clearance for the device in September. Now the company is planning to expand its presence in the commercial market, focusing on headache specialists and neurologists at headache centers in the U.S.-30-
Gliknik receives $15M payment from Pfizer after reaching clinical milestone
MindX, a startup developing brain-controlled smartglasses, names Julia Brown as CEO
JPMorgan Chase is expanding its Entrepreneurs of Color Fund to offer loans in Baltimore
Arrive ready to grow at 14 West
Maryland E-Nnovation initiative provides matching funds for tech-focused research endowments
Digital Harbor Foundation receives $450K grant from The Harry and Jeanette Weinberg Foundation
Maryland companies raised more than $1B in venture funding in 2018
The Washington Post is reprogramming the way news breaks
Sign-up for daily news updates from Technical.ly Baltimore